MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.

Abstract	In this study, we examined the role of the miRNA miR-770-5p in cisplatin chemotherapy resistance in ovarian cancer (OVC) patients. miR-770-5p expression was reduced in platinum-resistant patients. Using a 6.128-fold in expression as the cutoff value, miR-770-5p expression served as a prognostic biomarker and predicted the response to cisplatin treatment and survival among OVC patients. Overexpression of miR-770-5p in vitro reduced survival in chemoresistant cell lines after cisplatin treatment. ERCC2, a target gene of miR-770-5p that participates in the NER system, was negatively regulated by miR-770-5p. siRNA-mediated silencing of ERCC2 reversed the inhibition of apoptosis resulting from miR-770-5p downreglation in A2780S cells. A comet assay confirmed that this restoration of cisplatin chemosensitivity was due to the inhibition of DNA repair. These findings suggest that endogenous miR-770-5p may function as an anti-oncogene and promote chemosensitivity in OVC, at least in part by downregulating ERCC2. miR-770-5p may therefore be a useful biomarker for predicting chemosensitivity to cisplatin in OVC patients and improve the selection of effective, more personalized, treatment strategies.
Authors	Henan Zhao, Xiaotang Yu, Yanfang Ding, Jinyao Zhao, Guang Wang, Xian Wu, Jiyong Jiang, Chun Peng, Gordon Zhuo Guo, Shiying Cui
Journal	Oncotarget (Oncotarget) Vol. 7 Issue 33 Pg. 53254-53268 (Aug 16 2016) ISSN: 1949-2553 [Electronic] United States
PMID	27449101 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents MIRN7977 microRNA, human MicroRNAs Xeroderma Pigmentosum Group D Protein ERCC2 protein, human Cisplatin
Topics	Antineoplastic Agents (therapeutic use) Apoptosis (drug effects, genetics) Cell Line, Tumor Cisplatin (therapeutic use) Drug Resistance, Neoplasm (genetics) Female Gene Expression Profiling (methods) Gene Expression Regulation, Neoplastic Humans In Situ Hybridization Kaplan-Meier Estimate MicroRNAs (genetics) Middle Aged Ovarian Neoplasms (drug therapy, genetics, metabolism) RNA Interference Xeroderma Pigmentosum Group D Protein (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!